Earnings Beat: Gland Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Gland Pharma Limited (NSE:GLAND) just released its latest quarterly results and things are looking bullish. The company beat expectations with revenues of ₹18b arriving 2.5% ahead of forecasts. Statutory earnings per share (EPS) were ₹19.22, 5.9% ahead of estimates. Earnings are an important time for investors, as they can track a company’s performance, look at what the analysts are forecasting for next year, and see if there’s been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Taking into account the latest results, the consensus forecast from Gland Pharma’s 14 analysts is for revenues of ₹74.8b in 2027. This reflects a meaningful 11% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to step up 16% to ₹79.33. Before this earnings report, the analysts had been forecasting revenues of ₹73.2b and earnings per share (EPS) of ₹75.65 in 2027. So there seems to have been a moderate uplift in sentiment following the latest results, given the upgrades to both revenue and earnings per share forecasts for next year.

View our latest analysis for Gland Pharma

With these upgrades, we’re not surprised to see that the analysts have lifted their price target 21% to ₹2,820per share. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Gland Pharma analyst has a price target of ₹3,350 per share, while the most pessimistic values it at ₹1,940. As you can see, analysts are not all in agreement on the stock’s future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Gland Pharma’s growth to accelerate, with the forecast 15% annualised growth to the end of 2027 ranking favourably alongside historical growth of 12% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 12% per year. Factoring in the forecast acceleration in revenue, it’s pretty clear that Gland Pharma is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Gland Pharma following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that in mind, we wouldn’t be too quick to come to a conclusion on Gland Pharma. Long-term earnings power is much more important than next year’s profits. We have forecasts for Gland Pharma going out to 2029, and you can see them free on our platform here.

We also provide an overview of the Gland Pharma Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.